Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels
National Institutes of Health · Hackensack University Medical Center · +9 more institutions
Abstract
Purpose T cells genetically modified to express chimeric antigen receptors (CARs) targeting CD19 (CAR-19) have potent activity against acute lymphoblastic leukemia, but fewer results supporting treatment of lymphoma with CAR-19 T cells have been published. Patients with lymphoma that is chemotherapy refractory or relapsed after autologous stem-cell transplantation have a grim prognosis, and new treatments for these patients are clearly needed. Chemotherapy administered before adoptive T-cell transfer has been shown to enhance the antimalignancy activity of adoptively transferred T cells. Patients and Methods We treated 22 patients with advanced-stage lymphoma in a clinical trial of CAR-19 T cells preceded by…
Citation impact
- FWCI
- 29.91
- Percentile
- 100%
- References
- 54
Authors
22- JNJames N. KochenderferCorresponding
National Institutes of Health, Hackensack University Medical Center, AbbVie (United States), China National Pharmaceutical Group Corporation (China), Seagen (Canada), Pharmacyclics (United States), National Cancer Institute, Center for Cancer Research, Bayer (France), Bristol-Myers Squibb (Switzerland), University of Rochester
- RSRobert Somerville
National Institutes of Health, Hackensack University Medical Center, AbbVie (United States), China National Pharmaceutical Group Corporation (China), Seagen (Canada), Pharmacyclics (United States), National Cancer Institute, Center for Cancer Research, Bayer (France), Bristol-Myers Squibb (Switzerland), University of Rochester
- TLTangying Lu
National Institutes of Health, Hackensack University Medical Center, AbbVie (United States), China National Pharmaceutical Group Corporation (China), Seagen (Canada), Pharmacyclics (United States), National Cancer Institute, Center for Cancer Research, Bayer (France), Bristol-Myers Squibb (Switzerland), University of Rochester
- VSVictoria Shi
National Institutes of Health, Hackensack University Medical Center, AbbVie (United States), China National Pharmaceutical Group Corporation (China), Seagen (Canada), Pharmacyclics (United States), National Cancer Institute, Center for Cancer Research, Bayer (France), Bristol-Myers Squibb (Switzerland), University of Rochester
- ABAdrian Bot
National Institutes of Health, Hackensack University Medical Center, AbbVie (United States), China National Pharmaceutical Group Corporation (China), Seagen (Canada), Pharmacyclics (United States), National Cancer Institute, Center for Cancer Research, Bayer (France), Bristol-Myers Squibb (Switzerland), University of Rochester
Topics & keywords
- Medicine
- Fludarabine
- Lymphoma
- Chemotherapy
- Chimeric antigen receptor
- Follicular lymphoma
- Cyclophosphamide
- Mantle cell lymphoma
- Good health and well-being